anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the cosmetic high in transparency, having a form trouble-modifying effect and a skin color trouble-modifying effect and excellent in the uniformity in the adhesion of the cosmetic to skins by strongly coating the surface of a clay mineral with an inorganic metal oxide. SOLUTION: The coating structure of an inorganic metal oxide coated on the surface of a clay mineral comprises the following coating powdery material (A), (B), (C) or (D). (A) The coating structure of the inorganic metal oxide comprises a composite material produced by forming a honeycomb-like structure on a film formed from ultrafine particles (average particle diameter: 50-250A). (B) The coating structure comprises a composite material formed from ultrafine particle films (average particle diameter is the same as above). (C) The coating structure comprises a composite material having a structure in which a film formed from ultrafine particles having an average particle diameter of 50-250Å and a honeycomb structure formed on the film are mixed.  (D) The coating structure comprises a composite material having a structure in which inorganic metal oxide particles having an average particle diameter of 0.08-0.8μm are embedded in the coating film structure of ultrafine inorganic metal oxide particles having an average particle diameter of 50-250Å. The coating power is preferably added to the cosmetic in an amount of 1-100wt.%.
Heterotopic ossification (HO) is characterized by the formation of pathological bone within the soft tissues. HO predominantly affects elbow joints and may be accompanied by tardy ulnar nerve palsy. This study aimed to explore the clinical and functional outcomes of patients with tardy ulnar nerve palsy caused by HO following surgical treatment, with a review of the relevant literature. A retrospective study was conducted on 4 patients with tardy ulnar nerve palsy caused by HO, who underwent anterior subcutaneous ulnar nerve transposition between 2015 and 2020. The patients were followed up for more than 1 year and the cause of HO was also identified. Clinical and functional outcomes were evaluating using the grip strength and pinch strength, visual analog scale (VAS) pain score and Quick disabilities of the arm, shoulder and hand (DASH) score. The causes of HO were repetitive micro-trauma in 1 case and excessive physical or rehabilitation therapy in 3 cases. The average follow-up period was 15.6 months (range; 12-21 months). The grip strength increased from an average of 14kg to 26.5kg. The pinch strength increased from an average of 1.5 kg to 3.63 kg. The Quick DASH score decreased from an average of 55.6 to 6.15. The VAS score for pain decreased from an average of 7 to 0.25. Rapid surgical treatment, including removal of the heterotopic bone and ulnar nerve anterior transposition, might improve outcomes in patients with tardy ulnar nerve palsy caused by HO.
The invention relates to a preparation method of ursolic acid as an immunologic adjuvant vaccine and use. The method comprises the following steps: co-culturing ursolic acid and H22 cell; preparing a hepatoma carcinoma cell vaccine by a normal method; and after the mouse is immunized, establishing a hepatoma carcinoma model. The result shows that after the vaccine with ursolic acid as the adjuvant immunizes the mouse, tumor growth of the tumor-bearing mouse is remarkably inhibited, the life elongation rate of the mouse is remarkably longer than that of a model group, and immune organs such as thymus are protected. The reproductive capacity of splenic lymphocyte is remarkably enhance. Contents of cell factors IL-2 and IL-4 in serum are remarkably enhanced, and contents and proportions of CD4+/CD8+T cells are remarkably enhanced. The immunofluorescence shows that serum of immunized mouse can be specifically combined with the H22 cell. High titer antibodies are detected in serum by ELISA (Enzyme-Linked Immuno Sorbent Assay). According to the hepatoma whole-cell vaccine with the ursolic acid as the adjuvant, the immunogenicity of the hepatoma vaccine can be effectively improved. The ursolic acid immunologic adjuvant vaccine obtained by the method is safe, non-toxic and wide in source, and the problem that the existing adjuvant vaccine is single in type, low in immunizing effect and inevitable in side effect can be overcome.
Standard retrograde sphincterotomy is performed on 750 patients using a standard sphincterotome. After deep bile duct cannulation, the standard sphincterotome, the Erlangen "pull-type" model, retrogradely cuts all layers of the wall of the duodenum and sphincter of Oddi. Precut papillotomy using a needle knife used in 20% to improve insert standard sphincterotome to bile duct. The number of patients with complications is calculated: bleeding, perforation, pancreatitis, cholangitis, acute cholecystitis, recurrent cholangiolithiasis, restenosis.
PURPOSE: A cosmetic composition for anti-aging containing medicinal herb extract is provided to enhance cell proliferation and metabolism, remove free radical, and improve skin anti-aging. CONSTITUTION: A cosmetic composition for skin anti-aging contains extract of Angelica Dahuricae Radix, Benincase hispida cogniaux, Cnidium officinale Makino, Polygonatum odoratum(MILLER) var. pluriflorum Ohwi, Aiasarum sieboldii Miquel, Thladiantha dubia Bunge, Prunus persica, Paeonia moutan Sims, Magnolia denudata Desrousseaux, Nardostachys chinensis Batal, and Bombyx mori Linn. The cosmetic composition for skin anti-aging additionally contains Panax ginseng C. A. Mey., Rehmannia glutinosa Libschitz var. purpurea Makino, and honey extract. The extract is isolated using water, ethanol, methanol, butanol, ethylacetate, butyleneglycol, hydrous propyleneglycol, hydrous glycerin, hydrous ethanol, or hydrous butyleneglycol. The cosmetic composition is used in the form of lotion, nutrition lotion, nutrition cream, massage cream, essence or pack.
Patients receive pembrolizumab IV over 30 minutes followed by modified vaccinia virus Ankara vaccine expressing p53 SC at least 30 minutes later once in weeks 1, 4, and 7. Patients may receive additional doses of pembrolizumab in weeks 10, 13, 16, and 19, for a maximum of 7 doses if there are no signs of progressive disease. Treatment continues in the absence of disease progression or unacceptable toxicity.
Methods and systems for monitoring compliance of a patient with a prescribed treatment regimen are described. Patient speech is detected during use of a communication system such as a mobile telephone and analyzed to determine compliance with a treatment for a brain-related disorder, for example. Speech data representing one or more patient speech pattern and an identity signal containing information used to determine presence/identity of the patient are transmitted from a circuitry-based system at the patient location to a monitoring location. Identity of the patient as user of the communication system is determined through, e.g., biometric or authentication techniques. Speech data is analyzed to determine whether a patient speech pattern matches one or more characteristic speech patterns. Outcome of the analysis is reported to a medical caregiver or other party, for example.
Patients with glaucoma come in and get an intraocular pressure check at baseline. They get a 5 minute foot massage and then have their intraocular pressure checked every 30 minutes over 2 hour span.
The investigation will be included 2 groups which include 30 individuals with non-specific chronic neck pain and 30 healthy individuals. In evaluation of participants, endurance of deep cervical flexor muscles will be measured using Stabilizer Pressure Biofeedback Unit with cranio-cervical flexion test. Pressure rise which increases from 20 mmHg to 30 mmHg with 2 mmHg increments will be performed in 5 stages. There are 10 seconds contractions at every stage and these contractions will be made 10 times. Endurance will be calculated by the cumulative performance index with the information obtained from this test. Neck position sense of 6-direction (flexion, extension, right-left lateral flexion and right-left rotation) will be measured by CROM device (cervical range of motion device). Joint position error will be calculated by taking the average of the absolute angular difference by 3 trial for each direction. Body balace will be measured by Balance Master System. Modified clinical test of sensory interaction balance (mCTSIB), limits of stability (LOS), rhythmic weight shift (RWS), unilateral stance (US), walk across (WA) and step/quick turn (SQT) will be performed.
Part I was a multiple-ascending dose-escalation in single participant cohorts. RO7172508 was administered intravenously once every 3 weeks (Q3W). The starting dose of RO7172508 was 65 microgram (mcg) and the maximum dose explored was 1.6 milligram (mg).
Women with severe hypertension should not be started on hormonal contraceptives (see CONTRAINDICATIONS).

An increase in blood pressure has been reported in women taking oral contraceptives and this increase is more likely in older oral contraceptive users and with continued use. Data from the Royal College of General Practitioners and subsequent randomized trials have shown that the incidence of hypertension increases with increasing concentrations of progestogens.

Women with a history of hypertension or hypertension-related diseases, or renal disease should be encouraged to use another method of contraception. If women with hypertension elect to use oral contraceptives, they should be monitored closely, and if significant elevation of blood pressure occurs, oral contraceptives should be discontinued. For most women, elevated blood pressure will return to normal after stopping oral contraceptives and there is no difference in the occurrence of hypertension among ever- and never-users.
OBJECTIVE: To gain insights into how proteases signal to connective tissues cells in the periodontium.
BACKGROUND: The connective tissue degradation observed in periodontitis is largely due to matrix metalloproteinase (MMP) release by gingival fibroblasts. Granzyme B (GzmB) is a serine protease whose role in periodontitis is undefined.
METHODS: Human gingival crevicular fluid (GCF) samples were obtained from sites with periodontal disease and healthy control sites. GzmB was quantified in the GCF ([GzmB]GCF ) by ELISA. Gingival fibroblasts (GF) were cultured in the presence or absence of recombinant GzmB. Culture supernatants were analyzed by ELISA to quantify GzmB-induced release of interstitial collagenase (MMP-1). In some experiments, cells were pre-treated with the inhibitor PD98059 to block MEK/ERK signaling. The protease-activated receptor-1 (PAR-1) was blocked with ATAP-2 neutralizing antibody prior to GzmB stimulation. Systemic MMP-1 levels were measured in plasma from wild-type (WT) and granzyme-B-knockout (GzmB-/- ) mice.
RESULTS: The [GzmB]GCF in human samples was ~4-5 fold higher at sites of periodontal disease (gingivitis/periodontitis) compared to healthy control sites, suggesting an association between GzmB and localized matrix degradation. GzmB induced a ~4-5-fold increase in MMP-1 secretion by cultured fibroblasts. GzmB induced phosphorylation of Erk1/2, which was abrogated by PD98059. GzmB-induced upregulation of MMP-1 secretion was also reduced by PD98059. Blockade of PAR-1 function by ATAP-2 abrogated the increase in MMP-1 secretion by GF. Circulating MMP-1 was similar in WT and GzmB-/- mice, suggesting that GzmB's effects on MMP-1 release are not reflected systemically.
CONCLUSION: These data point to a novel GzmB-driven signaling pathway in fibroblasts in which MMP-1 secretion is upregulated in a PAR1- and Erk1/2-dependent manner.
Participants randomized to the control condition will receive UC during the 12-week period following randomization. Usual care consists of emergency assistance and access to legal name/gender marker change. After the RCT follow-up period is complete, waitlist control participants will be offered delayed access to the same intervention that is provided immediately to intervention arm participants.
The invention relates to a bacterial strain or a combination of bacterial strains, selected from the group consisting of: a  Chryseobacterium massiliae  strain, a  Flavobacterium sp.  strain with at least 95% or more Average Nucleotide Identity (ANI) value with the  Flavobacterium sp.  strain whose genome comprises SEQ ID NO:1 or as identified by Accession Number No. I-5481 deposited at the Collection Nationale De Culture De Microorganismes (CNCM) on January 24, 2020, and variants thereof, for use as a probiotic in fish(es). The bacterial strain(s) may has(ve) at least 95% or more Average Nucleotide Identity (ANI) value with the  Chryseobacterium massiliae  strain whose genome comprises SEQ ID NO:2 or as identified by Accession Number No. I-5479 deposited at the CNCM on January 24, 2020, and/or the  Flavobacterium sp.  strain whose genome comprises SEQ ID NO: 1 or as identified by Accession Number No. I-5481 deposited at the CNCM on January 24, 2020, respectively, or variants thereof. Probiotic use may be directed to preventing or minimizing infections by  Flavobacterium columnare  in fishes. The invention also concerns the said deposited bacterial strains, or probiotic compositions or food products or kits comprising the same, and a method to identify bacterial strain(s) that are probiotic against a pathogen infection.
BACKGROUND: Population-based studies examining the prevalence of trigeminal neuralgia (TN) and persistent idiopathic facial pain (PIFP) are rare, and data on TN prevalence in Türkiye are very limited, with the prevalence of PIFP being unknown. This study aimed to determine the prevalence of TN and PIFP in Türkiye.
MATERIALS AND METHODS: This population-based epidemiological study has a cross-sectional and descriptive design, and it was carried out in Afyonkarahisar, Türkiye. Participants aged 18 years and older were screened by using a self-assessment form to determine potential patients with TN or PIFP.
RESULTS: A total of 19,237 individuals were included in this study, of which 17,223 responded to the survey questions. TN was diagnosed in 17 individuals, and the prevalence of TN was calculated as 98.5 per 100,000. PIFP was diagnosed in 35 patients, and the prevalence of PIFP was calculated as 202 per 100,000. The mean age of the patients with TN was 54.29 ± 12.98 years, the mean age of patients with PIFP was 49.80 ± 16.10 years, and the female-to-male ratio was 1.13/1 for TN and 2.18/1 for PIFP.
CONCLUSION: The prevalence of PIFP in Türkiye has been reported for the first time by this study. Additionally, a much higher prevalence of TN was found when compared to previous study.
With the success of treatment, the survival period of Acquired immunodeficiency syndrome (AIDS) patients is prolonged. Compared with non-HIV-infected persons of the same age, HIV-infected persons have a relatively higher incidence of metabolic syndrome (MS). The main purpose of this study is to estimate the prevalence of common Non-AIDS related Comorbidities (NARC) among HIV-infected persons This study is a cross-sectional survey, purposive and snowball sampling will be applied. The recruitment information is released through channels such as AIDS case managers, AIDS non-government organizations, and social networks of HIV-infected people all around Taiwan. The expected sample size is 400 HIV-infected persons over the age of 30, after signing a written consent form, a test will be conducted, including the collection of demographic data, questionnaire data collection with physical activity scale, mini-nutrition assessment scale, and depression self-test scale, and measurement of physiological parameters using instruments including a gripper, body composition meter, sphygmomanometer, blood glucose, and lipid monitor, tape measure. The Chi-square test and independent sample T-test are used to compare the differences in the categorical and continuous data of each variable, and the structural equation model is used to conduct path analysis of the research framework. The research results can be used as precise care recommendations for the development of preventive medicine and healthy aging for HIV-infected persons.
Routine follow-up coronary angiography after percutaneous coronary intervention has been performed to detect restenosis in a lot of PCI centers in Japan. On the other hand, previous studies reported that routine follow-up coronary angiography might lead to unnecessary reinterventions in asymptomatic patients. In this situation, the effect of routine follow-up coronary angiography on long-term clinical outcomes remains unknown. The purpose of this study is to evaluate the long-term clinical impact of routine follow-up coronary angiography after PCI compared with clinical follow-up alone. The primary endpoint of this study is a composite of death/myocardial infarction/stroke/emergency hospitalization for acute coronary syndrome/hospitalization for congestive heart failure at three-year after percutaneous coronary intervention. The design of this study is almost all-comer design enrolling patients received PCI without any exclusion criteria.
The control procedure corresponds to standard management of BCC with an initial diagnosis based on skin biopsy (standard management arm). The biopsy will be performed according to the standard practice of each center, using a 2 to 6 mm punch or shave biopsy, with prior injection of a local anesthetic. A final evaluation with the deepLive™ device will also be performed during the 1-year follow-up.
BACKGROUND AND PURPOSE: <p>Delirium is a common complication developing in el­der­ly patients. Therefore, it is important to diagnose delirium earlier. Family caregivers play an active role in early diagnosis of de­lirium and build a bridge between health pro­fessionals and patients. The purpose of this research was to achieve the validity and reliability of the Turkish version of the Informant Assessment of Geriatric Delirium Scale (I-AGeD).</p>.
METHODS: <p>This is a methodological study. The sample comprised 125 caregivers ac­cepting to participate in the study and offering care to older patients with hip fracture aged ≥60 years. Data were gathered preoperatively and on postoperative days 0, 1 and 2. After achieving the linguistic and content validity of the scale, the known-groups comparison was used to achieve its construct validity. The ROC curve analysis was made to determine the sensitivity and specificity of the scale. Item-total correlations, item analysis based on the difference between the upper 27% and lower 27%, Kuder–Richardson 20 (KR-20) coefficient and parallel forms reliability with the NEECHAM Confusion Scale were adapted to assess discriminant indices of the items in the I-AGeD.</p>.
RESULTS: <p>The item-total correlation coeffi­cients of the scale ranged from 0.54 to 0.89 and KR-20 coefficient ranged from 0.09 to 0.91 depending on the measurement times. According to the ROC curve analysis, the sensitivity and specificity of the scale were ≥ 91% and ≥ 96% respectively. The parallel forms reliability analysis showed a highly significant, strong negative relation at each measurement between the I-AGeD and the NEECHAM Confusion Scale. </p>.
CONCLUSION: <p>The I-AGeD is valid and reliable to diagnose delirium in older Turkish patients in perioperative processes.</p>.
PURPOSE:To provide new compounds useful as an intermediate for synthesis of an antineoplastic antibiotic M/43-37 F11. CONSTITUTION:Compounds of formula I (R<1> is a lower alkyl or an electron attracting substituent is an electron attractive substituent group; X is a halogen). The above-mentioned compounds can be obtained by introducing an electron attractive group into the hydroxyl group of a compound of formula II (R<3> is H, an electron attractive group or a lower alkyl) and then reacting a halogenation agent therewith in a radical condition. Introduction of the electron attractive group is carried out by adding and reacting an acylation agent (e.g. acetic acid anhydride) or a sulfonation agent (e.g. p-toluenesulfonic acid chloride) therewith. As the radical condition, addition of a radical initiator (e.g. azobisisobutylo-nitrile) or irradiation of light is used. In addition, an antibiotic M-143-37 F11 is obtained by treating the compound of formula I with a Lewis acid or hydrolyzing it in an acidic condition, then reacting formula R<6>-COOY (R<6> is H or a lower alkyl; Y is H, an alkaline metal or an organic base) therewith and subsequently hydrolyzing the resultant compound.
After 3 months, participants will be invited to participate in the intervention. No additional measures or outcomes will be recorded.
Amyloid β (Aβ) aggregates are considered as possible targets for therapy and/or diagnosis of Alzheimer disease (AD). It has been previously shown that curcumin targets Aβ plaques and interferes with their formation, suggesting a potential role for prevention or treatment of AD. In the present invention, curcumin-derivatives with improved physicochemical properties were synthesized and a "click chemistry" as well as a conventional liposome preparation method, were used to generate nanoliposomes decorated with the curcumin derivatives. These derivatives were designed to maintain the planar structure required for interaction with Aβ, as directly confirmed by Surface Plasmon Resonance experiments. Surface Plasmon Resonance experiments, measuring the binding of flowing liposomes to immobilized Aβ1-42, indicated that the liposomes exposing curcumin derivatives have extremely high affinity for Aβ1-42 fibrils (1-5 nM), likely because of the occurrence of multivalent interactions. The present invention describes the synthesis of the curcumin derivatives and the preparation and characterization of new nanoliposomes with a very high affinity for Aβ1-42 fibrils, to be exploited as vectors for the targeted delivery of new diagnostic and therapeutic molecules for AD.
The project was a 5-year prospective randomized clinical trial which conducted a direct comparison of the VTC and in-person modalities using rigorous methodology and a sophisticated analysis of equivalency between clinical and process outcome domains. In addition, cost effectiveness of this modality will be addressed. Approximately 130 combat Reservists, National Guardsmen, or veterans were recruited from multiple clinical sites. Prospective participants received a comprehensive assessment at baseline to determine eligibility. The exclusion criteria selected are consistent with large PTSD randomized clinical trials as well as research using the CPT protocol with military populations with PTSD. The treatment was delivered twice a week over 6 weeks by a doctoral level psychologist. Quality control procedures were incorporated into the study's design to ensure integrity, fidelity and standard administration of the CPT intervention across both conditions. Participants received additional assessments at mid-treatment, immediately post-treatment, and at 3 and 6 months post-treatment. Outcome domains include: 1) clinical outcomes (symptom severity, social functioning); 2) process outcomes (perception of treatment, satisfaction, group therapy alliance, treatment compliance, and attrition and treatment credibility); and (3) cost-effectiveness outcomes.